Investigation of 6-thioguanine as a strategy to overcome methotrexate resistance in a mouse model of leptomeningeal carcinomatosis
Journal of Neuro-Oncology · 2026
DOI: 10.1007/s11060-025-05321-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Hidemitsu Nakagawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nozaki Tokushukai Hospital, 10-50 Tanigawa, 2-Chome, Daito City, Osaka, 574-0074, Japan. nakagawa.hide@tokushukai.jp. Hauptthemen laut MEDLINE: Methotrexate, Meningeal Carcinomatosis, Thioguanine, Drug Resistance, Neoplasm. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Leptomeningeal carcinomatosis (LC), the dissemination of malignant cells into the cerebrospinal fluid, occurs in 3–5% of patients with solid tumors and is being recognized more frequently due to prolonged survival with systemic therapies. The prognosis remains dismal, with a median survival of 4–8 weeks. Methotrexate (MTX), the current standard treatment, is often compromised by resistance through dihydrofolate reductase (DHFR) upregulation and by neurotoxicity at high doses, underscoring the need for alternative therapeutic approaches.
Methods
An MTX-resistant subline (R-MM46) was established from a murine mammary carcinoma. Resistance was confirmed by increased DHFR activity, enhanced drug efflux, and apoptosis resistance, and validated in an LC mouse model. Metabolic alterations were assessed by measuring phosphoribosyl pyrophosphate (PRPP), hypoxanthine-guanine phosphoribosyltransferase (HGPRT), and thymidine kinase (TK). The therapeutic efficacy of 6-thioguanine (6-TG), which targets the salvage pathway, was evaluated in vivo.
Results
R-MM46 cells exhibited a 6–7-fold increase in DHFR activity, together with upregulation of P-glycoprotein and Bcl-2. In the LC mouse model inoculated with R-MM46 cells, MTX treatment failed to prolong survival. R-MM46 cells demonstrated PRPP accumulation and increased HGPRT and TK activity, consistent with activation of the salvage pathway. Oral 6-TG significantly extended survival, with the greatest benefit observed when administered sequentially 2–6 h after MTX.
Conclusion
Sequential 6-TG administration capitalizes on salvage pathway activation in MTX-resistant LC and may represent a promising therapeutic strategy to overcome MTX resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Nozaki Tokushukai Hospital, 10-50 Tanigawa, 2-Chome, Daito City, Osaka, 574-0074, Japan. nakagawa.hide@tokushukai.jp.
- Research Institute, Nozaki Tokushukai Hospital, Daito City, Osaka, Japan. nakagawa.hide@tokushukai.jp.
- Research Institute, Nozaki Tokushukai Hospital, Daito City, Osaka, Japan.
- Nihon Seimei Hospital, Osaka City, Osaka, Japan.
- Department of Neurosurgery, Nozaki Tokushukai Hospital, 10-50 Tanigawa, 2-Chome, Daito City, Osaka, 574-0074, Japan.
ORCID-Profile: Hidemitsu Nakagawa, Yoshihiro Yui
Zitieren
APA
Nakagawa, H., Yui, Y., Suzuki, T., Tamura, M., Yamada, M., & Kawaichi, M. (2026). Investigation of 6-thioguanine as a strategy to overcome methotrexate resistance in a mouse model of leptomeningeal carcinomatosis. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-05321-5
Vancouver
Nakagawa H, Yui Y, Suzuki T, Tamura M, Yamada M, Kawaichi M. Investigation of 6-thioguanine as a strategy to overcome methotrexate resistance in a mouse model of leptomeningeal carcinomatosis. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-025-05321-5
BibTeX
@article{Nakagawa2026,
author = {Nakagawa, Hidemitsu and Yui, Yoshihiro and Suzuki, Tsuyoshi and Tamura, Masakazu and Yamada, Masanobu and Kawaichi, Masashi},
title = {Investigation of 6-thioguanine as a strategy to overcome methotrexate resistance in a mouse model of leptomeningeal carcinomatosis},
journal = {Journal of Neuro-Oncology},
year = {2026},
doi = {10.1007/s11060-025-05321-5}
}
EUVIMED